The Health Resources and Services Administration (HRSA) has published the approved manufacturer plans for the 340B Rebate Model Pilot program, covering 21 drugs from 10 manufacturers. Novo Nordisk has opted not to participate in the pilot, and AstraZeneca has excluded Calquence from its approved plan. FQHC 340B Compliance has developed a Rebate Drug Cost & Interest Impact Calculator to estimate the financial impacts of the rebate model.